Pipeline: New therapies to come for debilitating eye diseases

November 12, 2020
Gretchyn M. Bailey, NCLC, FAAO, Editor in Chief, Content Channel Director

Bernard Gilly, PhD

CEO, Gensight Biologics

New drug from Gensight Biologics hits pipeline

GenSight Biologics has developed a therapy for Leber hereditary optic neuropathy (LHON), called Lumevoq. The drug has been submitted for approval in Europe, and the company plans to submit for U.S. Food & Drug Administration approval in late 2021.

Dr. Gilly explains the mechanism of action for Lumevoq and provides a look into the GenSight Biologics pipeline for the future.

Related: Myopia control data and whats to come with Dr. Noel Brennan